SCHEMBL169260

SCHEMBL169260

Nc1cnc2ncccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.52
KDM4E B2RXH2 3/20 0.52
ATM Q13315 2/20 0.52
TP53 P04637 2/20 0.52
HSP90AA1 P07900 2/20 0.52
TSHR P16473 2/20 0.52
HTT P42858 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
ALDH1A1 P00352 2/20 0.52
HSD17B10 Q99714 2/20 0.52
HSP90AB1 P08238 1/20 0.52
CASP1 P29466 1/20 0.52
NUDT1 P36639 1/20 0.41
ACP1 P24666 1/20 0.40
NPC1 O15118 5/20 0.39
CCR1 P32246 2/20 0.39
CCR5 P51681 2/20 0.39
CCR8 P51685 2/20 0.39
CASP6 P55212 1/20 0.39
RAB9A P51151 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30283008 1.00 MAPT (0.52) MAPTKDM4EATMTP53HSP90AA1
SCHEMBL29859744 1.00 MAPT (0.52) MAPTKDM4EATMTP53HSP90AA1
Hydrochloric Acid SCHEMBL29933717 0.98 MAPT (0.50) MAPTKDM4EATMTP53HSP90AA1
Hydrochloric Acid SCHEMBL30397052 0.98 MAPT (0.50) MAPTKDM4EATMTP53HSP90AA1
SCHEMBL15217632 0.80 CCR1 (0.62) MAPTKDM4EATMTP53HSP90AA1
SCHEMBL4987651 0.79 KDM4E (0.38) MAPTKDM4EATMTP53HSP90AA1
SCHEMBL2619133 0.75 CCR1 (0.67) KDM4EALDH1A1ACP1CCR1CCR5
SCHEMBL29862389 0.75 HTT (0.47) MAPTKDM4ETP53HSP90AA1TSHR
SCHEMBL18459627 0.75 ACP1 (0.40) MAPTKDM4ETP53HSP90AA1TSHR
SCHEMBL276491 0.75 ACP1 (0.43) MAPTKDM4ETP53HSP90AA1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116813938-A Conjugated small molecule modified hydrogel and preparation method thereof 金陵科技学院 2023-09-29 CN claimed
CN-116217481-A Naphthalimide fluorescent dye and synthetic method and application thereof 中国科学院大连化学物理研究所 2023-06-06 CN claimed
EP-2699572-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Origenis GmbH (DE) 2014-02-26 EP claimed
WO-2012143143-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2012-10-26 WO claimed
CN-102015651-A Compounds and compositions as TLR activity modulators IRM LLC 2011-04-13 CN claimed
US-12612424-B2 HPK1 inhibitors and uses thereof REGOR PHARMACEUTICALS, INC. (US) 2026-04-28 US disclosed
US-20250230155-A1 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS VANDERBILT UNIVERSITY 2025-07-17 US disclosed
CN-115362155-B Arylamine derivative, preparation method and medical application thereof 中国医药研究开发中心有限公司 2024-06-18 CN disclosed
US-20240165243-A1 EGFR DEGRADERS AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2024-05-23 US disclosed
EP-4304727-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2024-01-17 EP disclosed
CN-117377669-A TYK2 inhibitor and application thereof 苏多生物科学有限公司 2024-01-09 CN disclosed
CN-117242072-A TYK2 inhibitor and application thereof 苏多生物科学有限公司 2023-12-15 CN disclosed
CN-101312975-A Method for 1h-imidazo[4,5-c]pyridines and analogs thereof COLEY PHARM GROUP INC (US) 2008-11-26 CN disclosed
EP-1954132-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME Renovis, Inc. (US) 2008-08-13 EP disclosed
EP-1937683-A1 METHOD FOR 1H-IMIDAZOÝ4,5-c¨PYRIDINES AND ANALOGS THEREOF Coley Pharmaceutical Group, Inc. (US) 2008-07-02 EP disclosed
WO-2007100758-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2007-09-07 WO disclosed
WO-2007035935-A1 METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-03-29 WO disclosed
CN-1922178-A Piperazine, [1,4] diazepane , [1,4] diazacyclooctane ([1,4] diazocane), and [1,5] diazacyclooctane ([1,5] diazocane) fused imidazo ring compounds 3M INNOVATIVE PROPERTIES CO (US) 2007-02-28 CN disclosed
EP-0275520-B1 SUBSTITUTED 1,8-NAPHTHYRIDINE DERIVATIVES AND FUNGICIDES CONTAINING THEM BASF Aktiengesellschaft (DE) 1991-12-11 EP disclosed
CN-1006386-B PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER SHINETSU CHEM IND CO (JP) 1990-01-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612424-B2 HPK1 inhibitors and uses thereof NEK11, NEK1, CSNK1A1 MAPT 4729/4885KDM4E 2717/4885ATM 825/4885
US-20240165243-A1 EGFR DEGRADERS AND METHODS OF USE EGFR, ERBB2, ERBB3 MAPT 2899/4885KDM4E 1405/4885ATM 1573/4885
US-20250230155-A1 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS CHRM5, CHRM4, CHRM1 MAPT 772/4885KDM4E 1122/4885ATM 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.